Neil Minkoff, MD; Ian Frank, MD; Ryan Bitton, PharmD, MBA; Jeffrey Crowley, MPH; and Carl Schmid, MBA explore the current landscape of HIV prevention with PrEP and discuss overcoming barriers to its use.
EP. 1: Overview of HIV Prevention with PrEP
A multidisciplinary panel of experts provides an overview of the economic burden of HIV and the role of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.
EP. 2: CDC PrEP Care System Process and Assessing Risk of HIV
Ian Frank, MD and Jeffrey Crowley, MPH describe the CDC PrEP Care System Process and eligibility criteria for receiving PrEP.
EP. 3: Initiating PrEP: Patient Clinical Evaluation
Carl Schmid, MBA and Ian Frank, MD discuss the process of initiating HIV PrEP beginning with a clinical patient evaluation.
EP. 4: Payer Barriers to PrEP
Experts in HIV provide insight into payer coverage of HIV PrEP and patient barriers for receiving PrEP.
EP. 5: Addressing Patient Persistence and Adherence to PrEP in the Clinical Setting
Ian Frank, MD and Jeffrey Crowley, MPH address HIV PrEP adherence and persistence issues in the clinical practice setting.
EP. 6: Challenges to Monitoring PrEP Adherence and Persistence
A multidisciplinary panel of experts discuss challenges to monitoring patient adherence and persistence to HIV PrEP.
EP. 7: Barriers to PrEP Uptake
Experts in HIV discuss methods to address the low rate of HIV PrEP uptake among at-risk individuals.
EP. 8: Improving PrEP Use Among Clinicians
Ian Frank, MD and Jeffrey Crowley, MPH provide insight into engaging clinicians for increased assessment of patients for PrEP.
EP. 9: Abandoned PrEP: Targeting Nonadherent Patients
Key opinion leaders in HIV discuss nonadherence to HIV PrEP and methods to address patient “walk away.”
EP. 10: Grade A Recommendation: Impact of USPSTF Grading on PrEP
Experts in HIV provide insight into the Grade A recommendation for HIV PrEP by the U.S. Preventive Services Task Force (USPSTF) and its impact on patients, clinicians, and payers.
EP. 11: PrEP Pipeline: Effects of USPSTF Grading
A multidisciplinary panel of experts discuss pipeline medications for PrEP and effects of the USPSTF grading on emerging therapies.
EP. 12: Ideal Patient Selection for Long-Acting Injectable PrEP
Key opinion leaders in HIV describe factors to consider when evaluating which patients may benefit from long-acting injectable PrEP therapies.
EP. 13: Future of PrEP
Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.
2 Clarke Drive Cranbury, NJ 08512